Takeda Pharmaceutical (4502) Stock Price, Fundamentals & Analysis

What 4502 does

Takeda Pharmaceutical (4502) is a stock listed on the Tokyo Stock Exchange in the Healthcare sector, specifically in the Drug Manufacturers – Specialty & Generic industry. The company researches, develops, manufactures, markets, and out-licenses pharmaceutical products across gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. It operates under brands such as Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA. It also has licensing and collaboration arrangements for product development and commercialization with partners including Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, and Zedira/Dr. Takeda Pharmaceutical is part of the Nikkei 225 index and has peers such as Astellas (4503), Shionogi (4507), and Chugai Pharmaceutical (4519).

Key numbers explained

• The current price is 5,969 JPY, reflecting the latest trading value of one share.
• The price change today of +1.43% shows the intraday percentage move relative to the previous close.
• The forward P/E ratio of 42.5 divides the current price by expected future earnings; a higher number can indicate that investors expect strong growth or are paying a premium for those expectations.
• The dividend yield of 3.42% tells you the annual dividend payment as a percentage of the current share price, a common way to compare income returns across stocks.
• The ex-dividend date of 29 Sept. 2026 is the cutoff: buyers on or after this date do not receive the next dividend payment.
• The share of earnings paid out as dividends of 167% means the company distributed more in dividends than it earned over the trailing twelve months, often funded from reserves or other sources.
• The beta of 0.1 suggests the stock has historically moved much less than the overall market, indicating lower volatility relative to the benchmark.
• The price-to-book ratio of 1.25 compares the market price to the company's book value per share, showing how the market values the firm relative to its net assets.

What to watch

Investors tracking Takeda Pharmaceutical (4502) often monitor its revenue growth, which has been 10.2% year over year on trailing twelve-month revenue of 4,62 tril. JPY, as top-line trends can signal demand and pipeline progress. The operating margin of 16.4% provides a view of core profitability before interest and taxes, while the negative profit margin of -3.5% and negative return on equity of -2.3% highlight that net earnings have been negative over the trailing twelve months. The debt-to-equity ratio of 73.2% indicates the level of debt relative to shareholders' equity, a factor that can affect financial flexibility. Upcoming catalysts include the next earnings date of 29 Oct. 2026, where results and guidance can shift sentiment. The 52-week range of 4,102 – 6,033 JPY and the 39,5% price change over the past year show the recent trading context. For broader context, the stock can be compared with peers such as Terumo (4543), Hoya (7741), and Kyōwa Hakkō Kirin (4151), and it is part of the Tokyo Stock Exchange stocks universe.